Norway has moved decisively to safeguard the country's biotech industry, committing $418 million in a new stimulus package to keep its developers alive through the credit crisis. The financial support is expected to prevent widespread bankruptcies. "This is the most active political move in Europe regarding support to the biotech industry," said Bjarte Reve, chief executive of the Oslo Cancer Cluster. Report